Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer
Go back to Daraxonrasib Demonstrates Unprecedented Overall Survival Benefit in Pivotal Phase 3 RASolute 302 Clinical Trial in Patients with Metastatic Pancreatic Cancer| (NASDAQ: RVMD) | Delayed: 165.83 +2.84 (1.74%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $162.99 | 52 Week High | $ | |||
| Open | $162.32 | 52 Week Low | $ | |||
| Day High | $166.23 | P/E | N/A | |||
| Day Low | $162.15 | EPS | $ | |||
| Volume | 864,888 | |||||
